Follow Me on Twitter

Monday, January 26, 2015

$SAMP--> KEEP ON WATCH BIG THINGS GOING ON HERE!! TODAY's PENNY STOCK RUNNER ~NEWS COMING FOR THIS GEM~


$SAMP L@@KiNG FOR A "BOUNCE" Off Support Here @ .0009
Can't wait to be uplisted off the OTC, Ticker change Needed S@@N~~

Big News: Official Filing of Share Reduction Increase Potential for $SAMP: 
http://nvsos.gov/sosentitysearch/CorpDetails.aspx?lx8nvq=iRePBNV%252fD2iSW7kmN6aHIg%253d%253d&nt7=0 




Usa Restaurant Funding Inc.  $SAMP 

 Hours of Operation: 10:00 AM to 10:00 PM – Monday thru Wednesday 
                                      10:00 AM to  2:00 AM – Thursday thru Saturdays   

http://bethelinn.com/site/wp-content/uploads/2011/01/NIK_0242.jpg

 Philosophy: “The Pho House Dallas” has adopted the human resource philosophy “You are your environment”.
All members of the establishment are an integral part
of its success, and  “The Pho House Dallas”  will strive 
to create an environment of mutual respect,fair treatment and equitable compensation.

USA Restaurant Funding Inc. (OTC) $SAMP
  
O/S 152 million  - Float 70 million


PHO HOUSE DALLAS c/o USA Restaurant Funding Inc. Chairman Jeff Love and CEO Tommy Hoang in Corporate Meeting below: 


 Pho House Dallas: Your NEW Nightlife Destination  -$SAMP
Pho House looks forward to welcoming the men of Alpha Phi Alpha Fraternity, Inc. - 
Xi Tau Lambda Chapter for Phrozen Phriday 
January 23, 2015











SIGN UP FOR PENNYAWARENESS.COM FREE NEWSLETTER @ http://www.pennyawareness.com

Risk is Greater but Higher Reward is possible with OTC Bulletin Board exchange stocks. Pinksheets or OTC Stocks, tend to be less stable, but they do need to meet some requirements and filings, but the companies traded don’t have to meet the same requirements as NASDAQ or NYSE companies.

 USA Restaurant, Inc. is a Euro Asian themed restaurant that is located in the City of Dallas, TX.  The restaurant is focused on Vietnamese cuisine and traditional Vietnamese hospitality. The location of the restaurant  offer patrons "something different" in an area swamped with Italian, American, and Mexican restaurants.  USA Restaurant, Inc.  will focus primarily on Euro Asian Cooking in an atmosphere that brings the city of Saigon Vietnam to the dining room. This includes providing a realistic atmosphere with authentic foods, upscale yet casual atmosphere, fully stocked wine and liquor, and house background music.  

Pho House Dallas, TX is owned by USA Restaurants, Inc. and trades over the OTC Markets (SAMP).  According to latest PR Pho House currently generates profit each month and draws many patrons and recent PR announced the signing of newly acquired leases for additional Pho House franchises in selected areas of Texas in 2015.  

If you've been in the market, you'd know that a ticker 

 change is coming here very soon to reflect the new 

 name of this newly merged company. 


A LOT OF VERY REAL CUSTOMERS HERE $$$$$$                                                             LOOKS LIKE REVENUES  $$$$

Popular Pho cuisine takes Dallas by storm

RECENT PRs

NEW LARGER LOCATION

Dallas, TX / ACCESSWIRE / December 01, 2014 / USA Restaurant Funding, Inc. (OTCPK: SAMP), formerly South American Properties, is pleased to announce that due to remarkable growth in business from the North Dallas area, it is moving its popular Pho House restaurant to a new, larger facility at 18020 N. Dallas Pkwy. To better serve its customers, the new facility has more dining space, easy access to the toll way, and improved parking options. The new location is scheduled to open its doors for business on Friday, December 5, 2014.

 January Profits for New Location

DALLAS, TX / ACCESSWIRE / January 12, 2015 / USA Restaurant Funding, Inc. (SAMP), is pleased to announce that its new Pho House restaurant location expects to net a profit for the month of January assisted by special event bookings. Tommy Hoang, CEO of USA Restaurant Funding stated, "Early profitability at restaurants is rare, and these results should contribute to SAMP's ability to open additional Pho House locations in the near term."

  
Pho House Far North Dallas  


Dallas, TX / ACCESSWIRE / December 01, 2014 / USA Restaurant Funding, Inc. (OTCPK: SAMP), formerly South American Properties, is pleased to announce that due to remarkable growth in business from the North Dallas area, it is moving its popular Pho House restaurant to a new, larger facility at 18020 N. Dallas Pkwy. 

With a private banquet room, exclusive chilled wine pantry, and DOUBLE THE SEATING COMPARED TO THE ORIGINAL LOCATION, Pho House Far North Dallas is anticipated to be another popular spot to accommodate large parties as well as corporate events.


"Early profitability at restaurants is rare, and these results should contribute to SAMP's ability to open additional Pho House locations in the near term."


With a private banquet room, exclusive chilled wine pantry, and DOUBLE THE SEATING COMPARED TO THE ORIGINAL LOCATION, Pho House Far North Dallas is anticipated to be another popular spot to accommodate large parties as well as corporate events.


PIVOT POINTS .003 / .0057 / .0106
Posted by at No comments:

$OXIS ~ Right now Largest Potential for the Marijuana Industry is in The Biotech Sector in Legalized Medical Marijuana!


$OXIS International   
$OXIS is on Facebook  




0 392


Connecting The Dots

In the OTC and Pinksheet markets investors have been cautious following the massive surge that the marijuana sector saw early last year with Colorado coming online as the very first state in the US to legalize the use of cannabis for recreational purposes.  Many companies trading in the penny stock markets did nearly anything they could do in order to take advantage of the mass appeal coming from this industry boom.  But now with a new year upon us, a seemingly smarter small and micro-cap stock investing public is looking for real value in the space and not just “another grow operation hoping for state licensing”.
Right now, attention seems to be in the biotech space as much of this “long term” potential for the marijuana industry is held by medical applications in such things as CBD’s and hemp derivatives to treat specific diseases like epilepsy and certain cancers.  If there’s one marijuana stock that’s remained in the “Top Ten”, it’s been GW Pharma (GWPH) and more recently, INSYS Therapeutics (INSY) both of which have novel therapies for numerous diseases such as different types of cancers.
In 2014 for example, the stock price for GWPH jumped to highs of $111.46 prior to pulling back to lows that were below $60 per share.
On the flip side, INSYS was recently granted orphan drug designation by the FDA and share prices have to highs of $47.18.
But what if you could have owned GWPH or INSY prior to prices jumping as high as they have? What if there was an opportunity to see these companies at levels around $0.02?  The obvious answer (in my opinion) would be “I would definitely buy”. A small investment at a price like that would be absolutely life-changing at today’s prices, let alone at the all time highs that these stock have seen over the last 12 months.
One company that has just come to light with a very strong team coupled with a similar vision and ground breaking assets is Oxis Biotech, Inc.  Now, I say recent because it was just last week that this company had a caveat emptor removed on OTCMarkets.com for being delinquent in its filings for quite some time.  As of Friday OXIS showed that it had successfully filed all delinquent financial statements bringing the company current.  In looking at the share structure, stock price, and market cap, this company looks like it could have what it takes to go to a higher exchange like the QB as long as it meets the requirements.  Furthermore, the company’s website just began to have updated content populated throughout its pages.

So What’s So Important That OXIS Could Be The Next INSY or GWPH?

First and foremost, Oxis International completed an additional round of financing in the amount of $1.25 million and an earlier round of financing completed in July of $1.425 million, brings the funding total for 2014 to $2.675 million. According to Oxis, it will use the proceeds to fund Oxis Biotech, Inc. activities related to the acquisition and/or licensing of cannabis related intellectual properties, marketing of Oxis International, Inc’s nutraceutical products, and general corporate purposes.
But you really need a firm and well-seasoned leadership team to be able to effectively appropriate funds like this.  Anthony Cataldo has been named Chief Executive Officer of Oxis International, Inc. Cataldo will continue to serve as Chairman of Oxis International, Inc. and President of Oxis Biotech, Inc. a wholly owned subsidiary of Oxis International. Inc. Cataldo has a track record of building successful biotechs.
From February 2011 to June 2013 Cataldo served as Chairman/CEO of Genesis Biopharma, inc. (Previous: GNBP), now known as Lion Biotechnologies, Inc., (LBIO) and currently trades over $8/share. Keep in mind that Cataldo created Lion/Genesis with the inclusion of assets acquired from the National Cancer Institute for the treatment of stage-four melanoma. With such a track record within the space and a penchant for success in biotech, this may be just the beginning for OXIS as it has just begun to see trading.  From early December up until recent, the stock price for Oxis Biotech has consistently remained in an uptrend moving as high as $0.0399 during the first few days of the new year.
Furthermore OXIS most recently announced that it executed definitive agreements licensing certain assets for the treatment of Multiple Myeloma and initiated a consulting agreement with University of Pittsburgh’s Professor, Dr. Xiang-Qun(Sean)Xie (one of the world’s foremost cannabinoid research scientists). The American Cancer Society’s estimates for multiple myeloma in the United States for 2015 are about 26,850 new cases of multiple myeloma and about 11,240 deaths from multiple myeloma alone.
The license agreement provides Oxis Biotech, Inc an exclusive worldwide license to develop and commercialize therapies for the treatment of Multiple Myeloma (a type of cancer that attacks plasma cells in bone marrow).  Dr. Xie joins Oxis Biotech as a consultant and member of the Science Advisory Board to further develop the assets licensed to Oxis Biotech, Inc.  Among the mile-long track record of amazing accomplishments that Dr. Xie holds (See below), he is a recipient of the 2014 American Association of Pharmaceutical Scientists (AAPS) Outstanding Research Achievement Award.
Mr. Cataldo stated, “I wanted to leverage Dr. Xie’s significant experience and technologies, much the same way I did when I acquired highly valued patents from the NCI (NIH) for stage 4 Melanoma from the National Cancer Institute to form Lion Biotechnologies, Inc. (LBIO)”.
In addition to this, University of Pittsburgh’s new Chancellor Patrick Gallagher encourages industry partnership of the University with OXIS.  This will further enhance the overall R & D capabilities of the company and could propel the company’s growth by leaps and bounds just as the case was for market leaders like GW Pharma.

R&D FACTS:

After studying the effects of cannabidiol on multiple myeloma cells, researchers found that; “CBD by itself or in synergy with BORT strongly inhibited growth, arrested cell cycle progression and induced MM cells death by regulating the ERK, AKT and NF-κB pathways with major effects in TRPV2+ cells.”
They conclude that; “These data provide a rationale for using CBD to increase the activity of proteasome inhibitors in MM.”
The study, which validates a recent National Institute of Health study which also found that cannabidiol can inhibit cancer cells, was conducted by researchers at the School of Pharmacy at the University of Camerino in Italy.
This is obviously a developing story but if history repeats itself with Cataldo at the helm of Oxis in addition to Dr. Xie in charge of building the infrastructure to deploy this tharepy, the real benefit could be to those early shareholders looking for untapped opportunity in the cannabis biotech sector. Right now this is a reality for OXIS and its shareholders.  The company has brought on both proven leadership and a world-renowned scientist for cannabinoid research immediately following the company becoming current in its filings and in my opinion could position Oxis to truly become the next big player in medical cannabis.

In a time where Bob Marley and Tommy Chong are producing their own brands of medical/recreational marijuana, the industry is booming with progress.  More states have come on board the legal marijuana money train and even more are beginning to put legislation plans in place to push through some kind of bill come the next election period.  The doors have opened even wider for real progress to be found within this burgeoning industry and from where I sit, it could be these medically focused organizations that will reap the biggest rewards from the forward looking nature that the biotech space has historically shown to have.

More About Dr. Xiang-Qun (Sean) Xie

Sean Xie, MD, PhD, EMBA is a tenured Professor at the Department of Pharmaceutical Sciences/Drug Discovery Institute at University of Pittsburgh and Associate Dean for Research Innovation at the School of Pharmacy. He is Principal Investigator of an integrated research laboratory of CompuGroup, BioGroup and ChemGroup, and Founding Director of Computational Chemical Genomics Screening Center. Dr. Xie is also Director/PI of NIH funded National Center of Excellence for Computational Drug Abuse Research. Dr. Xie holds joint faculty positions at the Departments of Computational System Biology and Structural Biology, and Pittsburgh Cancer Institute MT/DD Program.
Xie is a charter member of the NIH BPNS Study Section Review Panel, an oversea expert reviewer for the Chinese Natural Science Foundation, ad hoc reviewer for the Netherlands Organizations for Scientific Research Council for Chemical Sciences, MCMB Foundation for MRC UK, and the Wellcome Trust Fund, Sir Henry Wellcome Fellowship, London, UK. He serves as an invited guest editor for AAPS Journal, Editorial Board of American Journal of Molecular Biology, and Associate Editor of BMC Pharmacology and Toxicology.
He was an invited international Assessment Panelist for Fudan University College of Pharmacy, a member of the Board of Directors of the Chinese Association of Professionals in Science and Technology, and a Chair of the CAPST Biomedical and Pharmaceutical Society. Dr. Xie also holds adjunct professor title in top institutes and colleges of pharmacy in China, including CAMS Tianjin Institute of Hematology Stem Cell Medical Center; Fudan, Shanghai Jiaotong, and Zhejiang Universities. In 2013, he was named an honorary professor of Chinese Academy of Medical Sciences & Peking Union Medical College.






Posted by at No comments:

Wednesday, January 14, 2015

$HNSS Websites & Updates S@@N! http://www.healthnostics.com ~ $HNSS Facebook at http://www.facebook.com/Healthnostics

   Wednesday Morning Expecting a RUN!!

 HNSS.PK

Healthnostics Completes Sale of Baked American.com

MedBioWorld.com to be Updated Adding Medical Cannabis Reference Channel



Dec 04, 2014 (eTeligis.com via COMTEX) -- NEW YORK, NY, United States, via ETELIGIS
 INC., 12/04/2014 - - Healthnostics, Inc. (OTC Pink: HNSS) (PINKSHEETS: HNSS),
is providing shareholders and interested parties this update on the development
 and progress of the Company. Significantly, Healthnostics has completed the sale 
of Baked American.com in an all-stock transaction with Stragenics, Inc., an OTCQB reporting company. 
With this transaction completed, we are pleased to announce initial development and project
plans for the coming year.  MedBioWorld.com, one of the largest on-line professional medical and
biotechnology directory resource and reference portal sites, is to undergo extensive new development 
bringing the site up to date utilizing the latest web development technologies. Plans include adding new
portal channels, including Medical Cannabis research journals, more blogs and other on-line professional 
resources. The Company is also pleased that the development team at Visual Flavors will continue to
work with the Company on this new endeavor. Additional development projects, potential acquisitions
and new operations are being evaluated and information on these will be forthcoming as it is available.
Please go to www.medbioworld.com, for periodic updates.

Forward-Looking Statements
This press release may contain certain statements that are not descriptions of historical information,
but are forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Exchange Act of 1934. These forward-looking statements refer to matters
that involve risks and uncertainties. Such statements reflect management's current
views and are based on certain assumptions.
Actual results could differ materially from the assumptions currently anticipated.

CONTACT:
Healthnostics, Inc.
Investor Relations
contact@healthnostics.com
SOURCE: Healthnostics , Inc.

   




      
Healthnostics, Inc. is a medical products manufacturer, system manufacturer, product distribution, and consulting 
company. Healthnostics' subsidiary, World Wide Wipes Co., is a major manufacturer and distributor of medical and
 general swabs, and alcohol prep pads. World Wide Wipes market includes wipes for medical, veterinary, 
disinfecting, and a variety of other uses. The Company places a priority on price, quality, and convenience, 
providing prompt, free shipping
World Wide Wipes is a manufacturer and distributor of medical and general swabs, and alcohol prep pads. 
World Wide Wipes produces alcohol prep pads in a Class "C" clean room production environment. 
A fully equipped laboratory is maintained that is staffed with a team of qualified personnel to ensure product 
manufactured in our facility complies with all regulatory requirements and meets all company and customer 
specifications and foremost satisfies our high standards for quality - the highest in the industry
For further information please visit Healthnostics www.healthnostics.com, and Worldwide Wipes Co. 
www.wipesco.com.  And visit us on Facebook at www.facebook.com/Healthnostics.


Company Contact Info

Investor Relations:

Healthnostics, Inc.

551 Fifth Avenue

Suite 1625

New York, NY 10017



  Contact:
Phone: (301) 956-3342


Products

 
About Us
World Wide Wipes manufactures products for medical, veterinary, disinfecting, and a variety of other uses. 
We are a versatile organization dedicated towards meeting our customers' needs, from private label prep pads, 
to sterile prep pads or to large or medium sized prep pads. The company's market ranges from cartons for 
individuals to truckloads for corporations.

World Wide Wipes manufactures for a number of large medical distributors located throughout North America and
 exports product internationally. The World Wide Wipes organization is dedicated to blending excellent customer 
service with competitively priced superior alcohol prep pads. The Company places a priority on price, quality, and 
convenience, providing prompt, free shipping.

World Wide Wipes is planning on adding new products -- BZK and Iodine Pads -- to the company product line in the
 near future.

MicroFill-2160:

MicroFill-2160 fill-and-seal machine is being designed to produce 2,160 medical pads per minute, which is nearly 
three times faster than other similar machines in use today. Further, MicroFill-2160 will be built with a footprint
substantially smaller than other machines, which means it will take up less clean-room space, and be manageable
 by fewer operators. These speed, space, and labor benefits will significantly reduce manufacturing costs, and
this breakthrough machine will make possible the company's soon-to-be-announced unique manufacturing and
 distribution concept. The company will seek a patent for MicroFill-2160.

MobileCleanRoom:

 Medical manufacturing requires the use of FDA-mandated clean rooms that meet specific standards of 
ventilation, clean air and clean surfaces, and contamination and environmental controls. MobileCleanRoom will be
a Class 100 clean room containing no more than 100 particles 0.5 micron diameter or larger per cubic foot of air.
Unlike modular or portable clean rooms, MobileCleanRoom is being designed as a complete manufacturing site on
 wheels specifically for MicroFill-2160, the Company's recently announced small footprint, high production machine.

Benefits include:
  • Low-cost, low-overhead manufacturing facility;
  • Onboard water purification system;
  • Rapid deployment to prime market locations;
  • Rapid business expansion;
  • Reduced utility usage;
  • Separate units for separate products. 
MedBioWorld™ is the premier online resource portal for medical and biotechnology professionals. It provides a
ccess to valuable information through directories, targeted search engines and specialized databases, as well as
through reference tools like dictionaries, calculators, blogs, and newsletters.

MedBioWorld also provides Health News Explorer for searching Reuters Health and Industry News using
proprietary keyword search, results clustering, find similar context search and term-suggest technology to
mine the 48,500 Reuters Health news articles resident on the MedBioWorld portal. Other research tools include
 medical and biotechnology disease databases, clinical trials, medical guidelines, education and training, and
 medical journal full-text articles and abstracts.


MedGuardian is a Web-based patient care monitoring and risk management system for hospitals. It provides 
automated data collection, reporting and analysis for improving clinical treatments and reducing medical errors.
Patient treatment issues such as clinical complications, unexpected outcomes or other medical issues can be 
monitored and tracked providing continuous, real-time analysis and improvement. Risk events of concern to a 
hospital, including information about patients,  visitors, and employees are also documented and tracked.


FamilyMedicalNet is a consumer site based on the concept of selecting the best information on
every possible health and medical subject from all over the Internet, including primary and
secondary sources that are determined to be reliable and up-to-date. The greatest focus, however,
is on steering the visitor to information from federal government health and medical Web sites,
associations, publications and databases.

FamilyMedicalNet.com is intended for all ages and stages of life. It is organized by Focus Groups
and Health Issues, giving immediate access to the information of interest to the visitor.
The search feature, in particular, brings up sources from government databases that are easy
to understand and are complete and up-to-date.


Posted by at 1 comment:
Subscribe to: Posts (Atom)